Peter Lichter
Overview
Explore the profile of Peter Lichter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
343
Citations
36095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Boskovic P, Wilke N, Man K, Lichter P, Francois L, Radlwimmer B
Neuro Oncol
. 2023 Sep;
26(2):251-265.
PMID: 37769206
Background: Glioblastoma is the most common malignant brain tumor in adults. Cellular plasticity and the poorly differentiated features result in a fast relapse of the tumors following treatment. Moreover, the...
12.
Wong J, Jassowicz L, Herold-Mende C, Seiffert M, Mallm J, Lichter P, et al.
BMC Bioinformatics
. 2023 Aug;
24(1):326.
PMID: 37653401
Background: Here we present scSNPdemux, a sample demultiplexing pipeline for single-cell RNA sequencing data using natural genetic variations in humans. The pipeline requires alignment files from Cell Ranger (10× Genomics),...
13.
Zapatka M, Borozan I, Brewer D, Iskar M, Grundhoff A, Alawi M, et al.
Nat Genet
. 2023 Mar;
55(6):1077.
PMID: 36944734
No abstract available.
14.
Francois L, Boskovic P, Knerr J, He W, Sigismondo G, Schwan C, et al.
Cell Rep
. 2023 Mar;
42(3):112217.
PMID: 36862549
No abstract available.
15.
Faehling S, Coelho M, Floerchinger A, Schneider C, Stilgenbauer S, Lichter P, et al.
Hemasphere
. 2023 Feb;
7(3):e840.
PMID: 36844182
Chronic lymphocytic leukemia (CLL) is a common and incurable B-cell malignancy. Recent therapeutic approaches that target the B-cell receptor signaling pathway include inhibition of phosphatidylinositol-3-kinase (PI3K). The PI3K isoform delta...
16.
Arseni L, Sharma R, Mack N, Nagalla D, Ohl S, Hielscher T, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672428
Glioblastoma is the most aggressive brain tumor in adults. Treatment failure is predominantly caused by its high invasiveness and its ability to induce a supportive microenvironment. As part of this,...
17.
Broseus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, et al.
Nat Commun
. 2023 Jan;
14(1):309.
PMID: 36658118
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide...
18.
Wahida A, Buschhorn L, Frohling S, Jost P, Schneeweiss A, Lichter P, et al.
Nat Rev Cancer
. 2022 Nov;
23(1):43-54.
PMID: 36434139
High-throughput methods to investigate tumour omic landscapes have quickly catapulted cancer specialists into the precision oncology era. The singular lesson of precision oncology might be that, for it to be...
19.
Francois L, Boskovic P, Knerr J, He W, Sigismondo G, Schwan C, et al.
Cell Rep
. 2022 Oct;
41(3):111524.
PMID: 36260995
The metabolic enzyme branched-chain amino acid transaminase 1 (BCAT1) drives cell proliferation in aggressive cancers such as glioblastoma. Here, we show that BCAT1 localizes to mitotic structures and has a...
20.
Patil P, Toprak U, Seufert J, Braun T, Bernhart S, Wiehle L, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3253-3256.
PMID: 36083597
No abstract available.